European Patent Office

T 0883/23 (Liposomal irinotecan drug combination/IPSEN) du 26.09.2025

Identifiant européen de la jurisprudence
ECLI:EP:BA:2025:T088323.20250926
Date de la décision
26 septembre 2025
Numéro de l'affaire
T 0883/23
Requête en révision de
-
Numéro de la demande
16758337.6
Langue de la procédure
Anglais
Distribution
Distribuées aux présidents des chambres de recours (C)
Téléchargement
Décision en anglais
Versions JO
Aucun lien JO trouvé
Autres décisions pour cet affaire
-
Titre de la demande
DRUG COMBINATION COMPRISING LIPOSOMAL IRINOTECAN, OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN FOR TREATING METASTATIC PANCREATIC CANCER
Nom du demandeur
Ipsen Biopharm Ltd.
Nom de l'opposant
Sandoz AG
Generics [UK] Limit
Chambre
3.3.07
Sommaire
-
Dispositions juridiques pertinentes
European Patent Convention Art 56European Patent Convention Art 87(1)Rules of procedure of the Boards of Appeal 2020 Art 012(6)
Mots-clés
Priority - same invention (no)
Late-filed evidence - should have been submitted in first-instance proceedings (yes)
Late-filed evidence - circumstances of appeal case justify admittance (no)
Inventive step - (yes)
Exergue
The Enlarged Board of Appeal determined in G 2/98 that it is a condition for the compliance with the requirement of "the same invention" that the claimed subject-matter is directly and unambiguously derivable from the earlier application. However, the Enlarged Board did not conclude that the requirement of "the same invention" is necessarily satisfied if this condition is fulfilled, irrespective of any technical information associated with the claimed subject-matter, which is only described in the subsequent patent application.
(see point 1.5 of the decision)
Affaires citantes
-

Order

For these reasons it is decided that:

The appeals are dismissed.